Skip to content
Licensed Unlicensed Requires Authentication Published by De Gruyter September 21, 2011

MTRR 66A>G polymorphism in relation to congenital heart defects

Ingrid M. van Beynum, Margreet Kouwenberg, Livia Kapusta, Martin den Heijer, Ivon J.M. van der Linden, Otto Daniels and Henk J. Blom

Abstract

Background: Evidence is accumulating that periconceptional folic acid supplementation may prevent congenital heart defects (CHD). The methionine synthase reductase (MTRR) enzyme restores methionine synthase (MTR) enzyme activity and therefore plays an essential role in the folate- and vitamin B12-dependent remethylation of homocysteine to methionine. We studied the influence of the MTRR 66A>G polymorphism on CHD risk. In addition, possible interaction between this variant and plasma methylmalonic acid (MMA) concentrations, as an indicator of intracellular vitamin B12 status, was investigated.

Methods: Case-control and case-parental studies were conducted to explore this association. In total, 169 CHD patients and 213 child controls, and 159 mothers with a CHD-affected child and 245 female controls were included.

Results: The maternal MTRR 66AG and GG vs. AA genotypes revealed an odds ratio (OR) of 1.3 (95% CI 0.72–2.20) and 1.3 (0.71–2.37), respectively. Family-based transmission disequilibrium analysis did not reveal a significant association of the foetal 66G allele with the development of a heart defect in children (χ2=2.94, p=0.086). Maternal 66GG genotype in combination with high MMA concentration (above the 80th percentile) was associated with a three-fold (OR 3.3, 95% CI 0.86–12.50) increased risk for all types of CHD in offspring.

Conclusions: These data indicate that maternal MTRR 66A>G polymorphism is not a risk factor for CHD. Maternal MTRR 66GG genotype with compromised vitamin B12 status may possibly result in increased CHD risk. In addition to folate, vitamin B12 supplementation may contribute to the prevention of CHD.

Clin Chem Lab Med 2006;44:1317–23.


Corresponding author: I.M. van Beynum, Children's Heart Centre, Radboud University Nijmegen Medical Centre, P.O. Box 9101, 6500 HB Nijmegen, The Netherlands Phone: +31-24-3614427, Fax: +31-24-3619052,

References

1. Bakker MK, van den Berg MD, Boonstra A, van Diem MT, Meijer WM, ter Beek L, et al. EUROCAT Northern Netherlands Registration of congenital anomalies (Tables 1981–2002). Groningen: Department of Medical Genetics University Medical Centre, 2005:1–56.Search in Google Scholar

2. Bruins CL, Temmermans AM. Kindercardiologie in Nederland in de tachtiger jaren [Pediatric cardiology in the Netherlands]. Verslag van NHS project 84-143: voorkomen en prognose van hart en vaatafwijkingen bij jeugdigen in Nederland [Report 84-143 of the Netherlands Heart Foundation]. The Hague: Netherlands Heart Foundation, 1990.Search in Google Scholar

3. Hoffman JI, Kaplan S. The incidence of congenital heart disease. J Am Coll Cardiol 2002; 39:1890–900.10.1016/S0735-1097(02)01886-7Search in Google Scholar

4. Tennstedt C, Chaoui R, Körner H, Dietel M. Spectrum of congenital heart defects and extracardiac malformations associated with chromosomal abnormalities: results of a seven year necropsy study. Heart 1999; 82:34–9.10.1136/hrt.82.1.34Search in Google Scholar

5. Czeizel AE, Dudas I. Prevention of the first occurrence of neural-tube defects by periconceptional vitamin supplementation. N Engl J Med 1992; 327:1832–5.10.1056/NEJM199212243272602Search in Google Scholar

6. MRC Vitamin Study Research Group. Prevention of neural tube defects: results of the Medical Research Council Vitamin Study. Lancet 1991;338:131–7.10.1016/0140-6736(91)90133-ASearch in Google Scholar

7. Smithells RW, Sheppard S, Schorah CJ, Seller MJ, Nevin NC, Harris R, et al. Possible prevention of neural-tube defects by periconceptional vitamin supplementation. Lancet 1980; 1:339–40.10.1016/S0140-6736(80)90886-7Search in Google Scholar

8. Botto LD, Khoury MJ, Mulinare J, Erickson JD. Periconceptional multivitamin use and the occurrence of conotruncal heart defects: results from a population-based, case-control study. Pediatrics 1996; 98:911–7.10.1542/peds.98.5.911Search in Google Scholar

9. Botto LD, Mulinare J, Erickson JD. Do multivitamin of folic acid supplements reduce the risk for congenital heart defects? Am J Med Genet 2003; 121A:95–101.10.1002/ajmg.a.20132Search in Google Scholar

10. Czeizel AE. Periconceptional folic acid containing multivitamin supplementation. Eur J Obstst Gynecol Reprod Biol 1998; 78:151–61.10.1016/S0301-2115(98)00061-XSearch in Google Scholar

11. Scalon KS, Ferencz C, Loffredo CA, Wilson PD, Correa-Villasenor A, Khoury MJ, et al. Periconceptional folate intake and malformations of the cardiac outflow tract. Epidemiology 1998; 9:95–8.10.1097/00001648-199801000-00019Search in Google Scholar

12. Shaw GM, O'Malley CD, Wasserman CR, Tolarova MM, Lammer EJ. Maternal periconceptional use of multivitamins and reduced risk for conotruncal heart defects and limb deficiencies among offspring. Am J Med Genet 1995; 59:536–45.10.1002/ajmg.1320590428Search in Google Scholar PubMed

13. van Beynum IM, Kapusta L, den Heijer M, Vermeulen SH, Kouwenberg M, Daniëls O, et al. Maternal MTHFR 677C>T is a risk factor for congenital heart defects: effect modification by periconceptional folate supplementation. Eur Heart J 2006; 27:981–7.10.1093/eurheartj/ehi815Search in Google Scholar

14. Hobbs CA, James SJ, Parsian A, Krakowiak PA. Jernigan SL, Greenhaw JJ, et al. Congenital heart defects and genetic variants in the methylenetetrahydrofolate reductase gene. J Med Genet 2006; 43:162–6.10.1136/jmg.2005.032656Search in Google Scholar

15. Junker R, Kotthoff S, Vielhaber H, Halimeh S, Kosch A, Koch HG, et al. Infant methylenetetrahydrofolate reductase 677TT genotype is a risk factor for congenital heart disease. Cardiovasc Res 2001; 51:251–4.10.1016/S0008-6363(01)00286-3Search in Google Scholar

16. Shaw GM, Iovannisci DM, Yang W, Finnell RH, Carmichael SL, Cheng S, et al. Risks of human conotruncal heart defects associated with 32 single nucleotide polymorphisms of selected cardiovascular disease-related genes. Am J Med Genet A 2005; 138:21–6.10.1002/ajmg.a.30924Search in Google Scholar

17. Storti S, Vittorini S, Iascone MR, Sacchelli M, Collavoli A, Ripoli A, et al. Association between 5,10-methylenetetrahydrofolate reductase C677T and A1298C polymorphisms and conotruncal heart defects. Clin Chem Lab Med 2003; 41:276–80.10.1515/CCLM.2003.043Search in Google Scholar

18. Wenstrom KD, Johanning GL, Johnston KE, DuBard M. Association of the C677T methylenetetrahydrofolate reductase mutation and elevated homocysteine levels with congenital cardiac malformations. Am J Obstet Gynecol 2001; 184:806–17.10.1067/mob.2001.113845Search in Google Scholar

19. Hobbs C, Cleves MA, Melnyk S, Zhao W, James JS. Congenital heart defects and abnormal maternal biomarkers of methionine and homocysteine metabolism. Am J Clin Nutr 2005; 81:147–53.10.1093/ajcn/81.1.147Search in Google Scholar

20. Kapusta L, Haagmans ML, Steegers EA, Cuypers MH, Blom HJ, Eskes TK. Congenital heart defects and maternal derangement of homocysteine metabolism. J Pediatr 1999; 135:773–4.10.1016/S0022-3476(99)70102-2Search in Google Scholar

21. Leclerc D, Wilson A, Dumas R, Gafuik C, Song D, Watkins D, et al. Cloning and mapping of a cDNA for methionine synthase reductase, a flavoprotein defective in patients with homocystinuria. Proc Natl Acad Sci USA 1998; 95:3059–64.10.1073/pnas.95.6.3059Search in Google Scholar PubMed PubMed Central

22. Olteanu H, Munson T, Banerjee R. Differences in the efficiency of reductive activation of methionine synthase and exogenous electron acceptors between the common polymorphic variants of human methionine synthase reductase. Biochemistry 2002; 41:13378–85.10.1021/bi020536sSearch in Google Scholar PubMed

23. Olteanu H, Banerjee R. Human methionine synthase reductase, a soluble P-450 reductase-like dual flavoprotein, is sufficient for NADPH-dependent methionine synthase activation. J Biol Chem 2001; 276:35558–63.10.1074/jbc.M103707200Search in Google Scholar

24. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, et al. A common variant in methionine synthase reductase combined with low cobalamine (vitamin B12) increases risk for spina bifida. Mol Genet Metab 1999; 67:317–23.10.1006/mgme.1999.2879Search in Google Scholar

25. Rasmussen K, Moelby L, Jensen MK. Studies on methylmalonic acid in humans. II. Relationship between concentrations in serum and urinary excretion, and the correlation between serum cobalamin and accumulation of methylmalonic acid. Clin Chem 1989; 35:2277–80.10.1093/clinchem/35.12.2277Search in Google Scholar

26. Pietrzyk JJ, Bik-Multanowski M, Sanak M, Twardowska M. Polymorphisms of the 5,10-methylenetetrahydrofolate and methionine synthase reductase genes as independent risk factors for spina bifida. J Appl Genet 2003; 44:111–3.Search in Google Scholar

27. Zhu H, Wicker NJ, Shaw GM, Lammer EJ, Hendricks K, Suarez L, et al. Homocysteine remethylation enzyme polymorphism and increased risk for neural tube defects. Mol Genet Metab 2003; 78:216–21.10.1016/S1096-7192(03)00008-8Search in Google Scholar

28. van der Linden IJ, den Heijer M, Afman LA, Gellekink HJ, Vermeulen SH, Kluijtmans LA, et al. The methionine synthase reductase 66A>G polymorphism is a maternal risk factor for spina bifida. J Mol Med 2006. In press.10.1007/s00109-006-0093-xSearch in Google Scholar PubMed

29. van Beynum IM, den Heijer M, Thomas CM, Afman L, Oppenraay-van Emmerzaal D, Blom HJ. Total homocysteine and its predictors in Dutch children. Am J Clin Nutr 2005; 81:1110–6.10.1093/ajcn/81.5.1110Search in Google Scholar PubMed

30. Keijzer MB, den Heijer M, Blom HJ, Bos GM, Willems HP, Gerrits WB, et al. Interaction between hyperhomocysteinemia, mutated methylenetetrahydrofolate reductase (MTHFR) and inherited thrombophilic factors in recurrent venous thrombosis. Thromb Haemost 2002; 88:723–8.10.1055/s-0037-1613292Search in Google Scholar

31. Besson WT, Kirby ML, van Mierop LH, Teabeaut JR II. Effects of the size of lesions of the cardiac neural crest at various embryonic ages on incidence and type of cardiac defects. Circulation 1986; 73:360–4.10.1161/01.CIR.73.2.360Search in Google Scholar PubMed

32. Kirby ML, Turnage KL, Hays B. Characterization of conotruncal malformations following ablation of cardiac neural crest. Anat Rec 1985; 213:87–93.10.1002/ar.1092130112Search in Google Scholar PubMed

33. Yelbuz TM, Waldo KL, Kumiski DH, Stadt HA, Wolfe RR, Leatherbury L, et al. Shortened outflow tract leads to altered cardiac looping after neural crest ablation. Circulation 2002; 106:504–10.10.1161/01.CIR.0000023044.44974.8ASearch in Google Scholar

34. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16:1215.10.1093/nar/16.3.1215Search in Google Scholar

35. Barbaux S, Kluijtmans LA, Whitehead AS. Accurate and rapid “multiplex heteroduplexing” method for genotyping key enzymes involved in folate/homocysteine metabolism. Clin Chem 2000; 46:907–12.10.1093/clinchem/46.7.907Search in Google Scholar

36. Gaughan DJ, Kluijtmans LA, Barbaux S, McMaster D, Young IS, Yarnell JW, et al. The methionine synthase reductase (MTRR) A66G polymorphism is a novel genetic determinant of plasma homocysteine concentrations. Atherosclerosis 2001; 157:451–6.10.1016/S0021-9150(00)00739-5Search in Google Scholar

37. Ewens WJ, Spielman RS. The transmission/disequilibrium test: history, subdivision, and admixture. Am J Hum Genet 1995; 57:455–64.Search in Google Scholar

38. Spielman RS, McGinnis RE, Ewens WJ. Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). Am J Hum Genet 1993; 52:506–16.Search in Google Scholar

39. Shields DC, Kirke PN, Mills JL, Ramsbottom D, Molloy AM, Burke H, et al. The “Thermolabile” variant of methylenetetrahydrofolate reductase and neural tube defects: an evaluation of genetic risk and the relative importance of the genotypes of the embryo and the mother. Am J Hum Genet 1999; 64:1045–55.10.1086/302310Search in Google Scholar

40. Jacques PF, Bostom AG, Selhub J, Rich S, Curtis ER, Eckfeldt JH, et al. Effects of polymorphisms of methionine synthase and methionine synthase reductase on total plasma homocysteine in the NHLBI Family Heart Study. Atherosclerosis 2003; 166:49–55.10.1016/S0021-9150(02)00204-6Search in Google Scholar

41. Gellekink H, den Heijer M, Heil SG, Blom HJ. Genetic determinants of plasma total homocysteine. Semin Vasc Med 2005; 5:98–109.10.1055/s-2005-872396Search in Google Scholar PubMed

42. Feix A, Winkelmayer WC, Eberle C, Sunder-Plassmann G, Fodinger M. Methionine synthase reductase MTRR 66A>G has no effect on total homocysteine, folate, and vitamin B12 concentrations in renal transplant patients. Atherosclerosis 2004; 174:43–8.10.1016/j.atherosclerosis.2003.12.036Search in Google Scholar PubMed

43. Waldo K, Miyagawa-Tomita S, Kumiski D, Kirby ML. Cardiac neural crest cells provide new insight into septation of the cardiac outflow tract: aortic sac to ventricular septal closure. Dev Biol 1988; 196:129–44.10.1006/dbio.1998.8860Search in Google Scholar PubMed

44. Poelmann RE, Gittenberger-de Groot AC. A subpopulation of apoptosis-prone cardiac neural crest cells targets to the venous pole: multiple functions in heart development? Dev Biol 1999; 207:271–86.10.1006/dbio.1998.9166Search in Google Scholar PubMed

45. Gezondheidsraad/Voedingsraad. Vervolgadvies inzake foliumzuurvoorziening in relatie tot neurale buisdefecten. [Advice concerning folic acid intake in respect of neural tube defects.] The Hague: Voorlichtingsbureau voor de Voeding, 1993.Search in Google Scholar

Received: 2006-7-19
Accepted: 2006-9-10
Published Online: 2011-9-21
Published in Print: 2006-11-1

©2006 by Walter de Gruyter Berlin New York